International Aids Vaccine Initiative
Clinical Trials
36
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (36 trials with phase data)• Click on a phase to view related trials
A Phase 1 Trial of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine, Administered to Healthy Adults Living Without and with HIV
- Conditions
- HIV
- Interventions
- Drug: GRAdHIVNE1 VaccineOther: Placebo
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- International AIDS Vaccine Initiative
- Target Recruit Count
- 120
- Registration Number
- NCT06617091
Mosaic HIV-1 Envelope Trimer Immunogens Administered to People Living with HIV (PLWH) in Africa
- Conditions
- HIV
- Interventions
- Drug: Investigational product HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM)
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- International AIDS Vaccine Initiative
- Target Recruit Count
- 40
- Registration Number
- NCT06449196
A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in IGRA Positive Adolescents and Adults Living in a TB Endemic Region.
- Conditions
- Tuberculosis (TB)
- First Posted Date
- 2024-02-22
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- International AIDS Vaccine Initiative
- Target Recruit Count
- 4300
- Registration Number
- NCT06272812
A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted
- Conditions
- Hiv
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- International AIDS Vaccine Initiative
- Target Recruit Count
- 8
- Registration Number
- NCT05983874
- Locations
- 🇳🇱
The Amsterdam University Medical Centers, Amsterdam, Netherlands
A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa
- Conditions
- Lassa Fever
- Interventions
- Drug: Day 1 Lower Dose (2×106 pfu)Drug: Day 1 Higher Dose (1×107 pfu)Drug: Placebo
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- International AIDS Vaccine Initiative
- Target Recruit Count
- 612
- Registration Number
- NCT05868733
- Locations
- 🇬🇭
Noguchi Memorial Institute for Medical Research (NMIMR), Accra, Ghana
🇱🇷PREVAIL_ John F. Kennedy Medical Center (JFK), Monrovia, Liberia
🇳🇬Walter Reed Program - Nigeria, Wuse, Nigeria
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
News
Turn Therapeutics Achieves Breakthrough in Room-Temperature Vaccine Stability
Turn Therapeutics has demonstrated 100% recovery of vesicular stomatitis virus (VSV) after 72 hours in an oil-based carrier at room temperature, potentially eliminating cold storage requirements for vaccines.
USAID Funding Freeze Threatens Global Clinical Trials and Infectious Disease Research
The US Agency for International Development (USAID) has suspended all foreign assistance funding, forcing the pause of multiple clinical trials and threatening ongoing research in HIV, tuberculosis, and malaria.